Dr Andrew Kuykendall talks to ecancer about data he presented at ASCO 2025 from the Phase 3 VERIFY trial.

The findings demonstrated that rusfertide, a hepcidin mimetic peptide, improved hematocrit control and reduced the need for phlebotomy in patients with polycythemia vera (PV).

The treatment was generally well tolerated, with no serious adverse events attributed to rusfertide. The findings suggest that rusfertide could be added to the standard of care for PV, particularly for patients who are phlebotomy-dependent despite current therapies.